Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024)

Historic Other financing activities for Ultragenyx Pharmaceutical (RARE) over the last 5 years, with Q3 2024 value amounting to $7.0 million.

  • Ultragenyx Pharmaceutical's Other financing activities changed N/A to $7.0 million in Q3 2024 from the same period last year, while for Dec 2024 it was $7.0 million, marking a year-over-year increase of 2510000.0%. This contributed to the annual value of $7.0 million for FY2024, which is 2510000.0% up from last year.
  • Ultragenyx Pharmaceutical's Other financing activities amounted to $7.0 million in Q3 2024.
  • Ultragenyx Pharmaceutical's Other financing activities' 5-year high stood at $7.0 million during Q3 2024, with a 5-year trough of -$147000.0 in Q3 2022.
  • For the 5-year period, Ultragenyx Pharmaceutical's Other financing activities averaged around $379266.7, with its median value being -$112000.0 (2021).
  • Its Other financing activities has fluctuated over the past 5 years, first crashed by 23939.39% in 2021, then skyrocketed by 11958.04% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other financing activities (Quarter) stood at -$87000.0 in 2020, then tumbled by 63.22% to -$142000.0 in 2021, then grew by 16.2% to -$119000.0 in 2022, then skyrocketed by 52.94% to -$56000.0 in 2023, then soared by 12600.0% to $7.0 million in 2024.
  • Its last three reported values are $7.0 million in Q3 2024, -$56000.0 for Q2 2023, and $28000.0 during Q1 2023.